Loading
A lung cancer trial that planned to start durvalumab the moment a surveillance blood test found tumour DNA, before any scan showed relapse; the registry lists it as complete with 30 participants.
MERMAID-2 was AstraZeneca's phase 3, double-blind trial of durvalumab against placebo for people with stage II to III non-small-cell lung cancer whose ctDNA became detectable during surveillance after curative treatment, the 'treat at molecular relapse' design. The registry records a start on 30 November 2020, a status of completed with 30 participants, primary completion on 31 May 2023 and study completion on 15 January 2024. Its small size is the reason the roadmap describes ctDNA-triggered escalation as unproven outside bladder cancer.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
30 enrolled.
95% CI 3.515 to NA; Figures from the ClinicalTrials.gov results section (first posted 2024-06-25), not from a publication · 95% CI 1.643 to 3.910
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Disease-free Survival (DFS)primary | Durvalumab | 15 | 3.9 months | - | - | link |
| Placebo | 15 | 2 months |
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tag ctdna-roadmap.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tag ctdna-roadmap.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tag ctdna-roadmap.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA) and the tag ctdna-roadmap.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Continuous and near-continuous ctDNA monitoring, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.